Are users smoking less, to compensate for the drug’s new potency? Or simply getting more stoned, more quickly? Is high-potency cannabis more of a problem for younger users or for older ones? For some drugs, the dose-response curve is linear: twice the dose creates twice the effect. For other drugs, it’s nonlinear: twice the dose can increase the effect tenfold, or hardly at all. Which is true for cannabis? It also matters, of course, how cannabis is consumed. It can be smoked, vaped, eaten, or applied to the skin. How are absorption patterns affected?
Given the uncertainties and handicaps associated with hemp, it is fortunate that there are compensating factors. As noted, as a crop hemp offers some real environmental advantages, particularly with regard to the limited needs for herbicides and pesticides. Hemp is therefore pre-adapted to organic agriculture, and accordingly to the growing market for products associated with environmentally-friendly, sustainable production. Hemp products are an advertiser’s dream, lending themselves to hyperbole (“healthiest salad oil in the world,” “toughest jeans on the market”). While the narcotics image of C. sativa is often disadvantageous, advertisers who choose to play up this association do so knowing that it will attract a segment of the consuming population. In general, the novelty of hemp means that many consumers are willing to pay a premium price. It might also be said that those who have entered the hemp industry have tended to be very highly motivated, resourceful, and industrious, qualities that have been needed in the face of rather formidable obstacles to progress.
In a study whose findings have not yet been published, he and a colleague, Daniel Friedman, found that patients receiving CBD in addition to their usual medicines had 39 percent fewer convulsive seizures than patients who remained on their normal drug regimen. Given that the study included only the most treatment-resistant patients, this is an “excellent response,” Devinsky says.
That’s our two cents worth. We are still reserching products with claims of effective pain relief and possibly something will work. As of right now if dot/gov can not point the now abandoned pain management patient to an effective pain management product, not willing to listen to our physicians or VERY negatively affected patients with a maximum, unilateral dosage of opioid medication new “policy”, then where do we turn for real, effective, pain management?